{"name":"Bp Consulting, Inc","slug":"bp-consulting-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Blink","genericName":"Blink","slug":"blink","indication":"Other","status":"marketed"},{"name":"Bromefenac","genericName":"Bromefenac","slug":"bromefenac","indication":"Other","status":"marketed"},{"name":"Alphagan","genericName":"Alphagan","slug":"alphagan","indication":"Other","status":"marketed"},{"name":"PEG-400","genericName":"PEG-400","slug":"peg-400","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"New PEG based artificial tear","genericName":"New PEG based artificial tear","slug":"new-peg-based-artificial-tear","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"PEG- 400 based artificial tear","genericName":"PEG- 400 based artificial tear","slug":"peg-400-based-artificial-tear","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"Xibrom and Pred Forte","genericName":"Xibrom and Pred Forte","slug":"xibrom-and-pred-forte","indication":"Post-operative inflammation and pain following cataract surgery","status":"marketed"},{"name":"Xibrom, and Optive","genericName":"Xibrom, and Optive","slug":"xibrom-and-optive","indication":"Postoperative ocular inflammation and pain following cataract surgery (Xibrom)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Istalol and Optive","genericName":"Istalol and Optive","slug":"istalol-and-optive","indication":"Glaucoma and ocular hypertension (Istalol)","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Xibrom","genericName":"Xibrom","slug":"xibrom","indication":"Pain","status":"marketed"}]}],"pipeline":[{"name":"Blink","genericName":"Blink","slug":"blink","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bromefenac","genericName":"Bromefenac","slug":"bromefenac","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alphagan","genericName":"Alphagan","slug":"alphagan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Istalol and Optive","genericName":"Istalol and Optive","slug":"istalol-and-optive","phase":"marketed","mechanism":"Istalol is a beta-blocker that reduces intraocular pressure by decreasing aqueous humor production, while Optive is a lubricating eye drop that provides ocular surface hydration and protection.","indications":["Glaucoma and ocular hypertension (Istalol)","Dry eye syndrome (Optive)"],"catalyst":""},{"name":"New PEG based artificial tear","genericName":"New PEG based artificial tear","slug":"new-peg-based-artificial-tear","phase":"marketed","mechanism":"PEG-based artificial tear provides lubrication and moisture to the ocular surface to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"PEG- 400 based artificial tear","genericName":"PEG- 400 based artificial tear","slug":"peg-400-based-artificial-tear","phase":"marketed","mechanism":"PEG-400 based artificial tear lubricates and protects the ocular surface by forming a protective film that retains moisture and reduces friction.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"PEG-400","genericName":"PEG-400","slug":"peg-400","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Xibrom","genericName":"Xibrom","slug":"xibrom","phase":"marketed","mechanism":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","indications":["Pain","Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""},{"name":"Xibrom and Pred Forte","genericName":"Xibrom and Pred Forte","slug":"xibrom-and-pred-forte","phase":"marketed","mechanism":"Xibrom (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, while Pred Forte (prednisolone acetate) is a corticosteroid that suppresses immune and inflammatory responses.","indications":["Post-operative inflammation and pain following cataract surgery","Ocular inflammation associated with ophthalmic surgery"],"catalyst":""},{"name":"Xibrom, and Optive","genericName":"Xibrom, and Optive","slug":"xibrom-and-optive","phase":"marketed","mechanism":"Xibrom is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye, while Optive is a lubricating eye drop that provides ocular surface hydration.","indications":["Postoperative ocular inflammation and pain following cataract surgery (Xibrom)","Dry eye disease/ocular surface disease (Optive)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNUXVBOE1sczlBVXJ4VHZBS2I1eXRLeWQ4WjROU0RaN3l3T2JHWXY4WFY2ZVNhUy1oTzlTRWp0bkZrVDdnTHVYU1Z3bkJHMUJZNTRLYUgyWVNXZnppNEdOUHZNckUxWkg1cU93R1otZlByRTEtTEd2bExwMC1maTdVd1pqazR4SWpLSllN?oc=5","date":"2024-12-13","type":"pipeline","source":"NPR","summary":"McKinsey & Company to pay $650 million for role in opioid crisis - NPR","headline":"McKinsey & Company to pay $650 million for role in opioid crisis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOR1dyZ3g1S2hHNXlpb0R1ZVRDSWJpSlNldG04WUtaekszMU1xeTdSdXkxalVzTVFLRXFSR2xCYTBmM1hFbFVUX2ZDcGMzeTN3UFpoRnFiZm5SZ0tZNW5UdmZPc29yZGlYYXo2dzI3Ti1KWS1xMGtwU2dIRHE5eVVRN2p2QzhJZTBRWTNzbXFXdw?oc=5","date":"2021-10-14","type":"pipeline","source":"Healthline","summary":"Blood Pressure Medications Recall Latest - Healthline","headline":"Blood Pressure Medications Recall Latest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBZODJwLXNXM211Q3hNYTNpU3BTR3pkM2M4SzQ4TXJIUW9HNEZKdFJWWEIxQmtBMnlHVTFkeWtnUVFZT2l5OVZzbHBwdl9aRmgzdDdOcm9hR3VfN25SOWxuem12d3k3ZldEa0dhLXU3aGl4bGVU?oc=5","date":"2019-09-19","type":"pipeline","source":"The Intercept","summary":"Purdue Pharma Hired PR Firm That Rebranded BP After Deepwater Horizon Spill - The Intercept","headline":"Purdue Pharma Hired PR Firm That Rebranded BP After Deepwater Horizon Spill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5FRGJaeWhHTUpLZDlyN0dVaHRjMllQeElkeHBJUURnWEY3dGtXYUVyZkxjbnFEZ1VGM2ljNGJOQW9YRnNJc2FKdU12ZG1iOEhMS2RuNXF3?oc=5","date":"2019-01-09","type":"pipeline","source":"hiroshima-u.ac.jp","summary":"Hiroshima University has ranked high in university rankings in Japan - hiroshima-u.ac.jp","headline":"Hiroshima University has ranked high in university rankings in Japan - hiroshima","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOUnNmZWtJb3FqVEwtRmtfajhaT0ZfWWpkOFBpQkg1ekh3b1RMUnVwSDZEYXlUQ1c1emdiOC0ya2ltZ2FKMnFpTWN1QlI5c0hMMEVMam5CUE1JYTZ3TE8xQUZuXzJtamFiVzhObjRQQWQwU2ZuemR6Tm9NVXkwZEJYSFo3VTdDczVWcjZ5dE81ZVBPZ9IBlwFBVV95cUxPYi00NDRhVGkxc3BNQnhyd1MxblJoNFlkanZnbmZMckVzdk9YTkl2SzUxeTh3NGJ2M1VBZTBSSnRSRlBBeWRDNXRiME8tOERucjFvX2NkRnRVeWVCbkFnaW05bDZZR2VYa1FWODdHYnVWcEYwOW1nNl9uMXpyLTRKdjFaZTBIM1gzTTN4M01YVHhVNXVneWQ4?oc=5","date":"2015-03-03","type":"pipeline","source":"Consultancy.uk","summary":"BP selects Accenture to improve customer experience - Consultancy.uk","headline":"BP selects Accenture to improve customer experience","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":10},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}